GENOMMA LAB INTERNACIONAL

Genomma Lab Internacional rises 0.98% as sales grow after a June product launch, with stable margins and an AI‑driven strategy poised for future expansion.

Genomma Lab Internacional’s Q3 2026 earnings show modest sales growth, a lift in flagship market share, and a profit boost from lower financing costs and favorable FX, positioning it strongly in Mexico’s OTC pharma market.